Intravenous Immune Globulin in Amyopathic Dermatomyositis - Report of Two Cases and Review of the Literature
John M. Cafardi1, Naveed Sami*, 2
Identifiers and Pagination:Year: 2015
First Page: 77
Last Page: 81
Publisher ID: TORJ-9-77
Article History:Received Date: 23/4/2015
Revision Received Date: 23/9/2015
Acceptance Date: 23/9/2015
Electronic publication date: 4/11/2015
Collection year: 2015
open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Amyopathic dermatomyositis (ADM) is a rare subtype of dermatomyositis which is often recalcitrant to immune suppressing treatments. Intravenous immunoglobulin (IVIG) has been used in the treatment of refractory dermatomyositis. We present two patients with severe ADM, who were treated with IVIG at 2 g/kg every four weeks. Both patients had a successful response and were able to taper the dosage of prednisone. We present both cases in describing IVIG as a rescue and maintenance steroid-sparing agent in the treatment of severe refractory ADM. We also review the treatment of refractory ADM with IVIg in the English literature.